P16 expression and its association with PD-L1 expression and FOXP3-positive tumor infiltrating lymphocytes in head and neck squamous cell carcinoma

被引:7
|
作者
Kim, Taeyeong [1 ]
Jung, Soon-Hee [1 ]
Kim, Soo-Ki [2 ]
Kwon, Hyeong Ju [1 ]
机构
[1] Yonsei Univ, Wonju Coll Med, Dept Pathol, Wonju, South Korea
[2] Yonsei Univ, Wonju Coll Med, Dept Microbiol, Wonju, South Korea
基金
新加坡国家研究基金会;
关键词
Head and neck squamous cell carcinoma; P16; HPV; PD-L1; Tumor infiltrating lymphocytes; IMMUNE CELLS; CANCER; HPV; IMMUNOTHERAPY; PROGNOSIS;
D O I
10.1007/s13273-019-0017-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Backgrounds: Human papilloma virus (HPV) infection is an important factor in development and prognosis of head and neck squamous cell carcinoma (HNSCC). It is also known that HPV infection could affect anti-cancer immunity. Methods: We examined the association between cancer immunity-related molecules and HPV infection, using immunohistochemical (IHC) staining for p16, PD-L1, and FOXP3 and real-time polymerase chain reaction for HPV. Results: The IHC staining for PD-L1 was positive in 30 out of 122 cases (24.6%) and p16 showed positivity in 68 out of 122 cases (55.7%). HPV was detected in 48 out of 122 cases (39.3%). P16 expression was significantly associated with PD-L1 expression (P=0.004), HPV infection (P=0.032), and the number of FOXP3-positive tumor infiltrating lymphocytes (P=0.009). PD-L1-positive or p16-positive HNSCC showed a worse prognosis than PD-L1-negative or p16-negative HNSCC. Conclusion: P16 expression may predict PD-L1 expression, and p16 expression may also be associated with the immune evasion of HNSCC.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [31] Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
    Strati, A.
    Koutsodontis, G.
    Papaxoinis, G.
    Angelidis, I.
    Zavridou, M.
    Economopoulou, P.
    Kotsantis, I.
    Avgeris, M.
    Mazel, M.
    Perisanidis, C.
    Sasaki, C.
    Alix-Panabieres, C.
    Lianidou, E.
    Psyrri, A.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 1923 - 1933
  • [32] Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
    Haddad, Robert, I
    Seiwert, Tanguy Y.
    Chow, Laura Q. M.
    Gupta, Shilpa
    Weiss, Jared
    Gluck, Iris
    Eder, Joseph P.
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Kang, Hyunseok
    Muro, Kei
    Albright, Andrew
    Mogg, Robin
    Ayers, Mark
    Huang, Lingkang
    Lunceford, Jared
    Cristescu, Razvan
    Cheng, Jonathan
    Mehra, Ranee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [33] Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma
    Garcia-Marin, Rocio
    Reda, Sara
    Riobello, Cristina
    Cabal, Virginia N.
    Suarez-Fernandez, Laura
    Vivanco, Blanca
    Alvarez-Marcos, Cesar
    Lopez, Fernando
    Llorente, Jose L.
    Hermsen, Mario A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [34] Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma
    Girolami, Ilaria
    Marletta, Stefano
    Fiorentino, Vincenzo
    Battocchio, Simonetta
    Cerbelli, Bruna
    Fiamengo, Barbara
    Gerosa, Clara
    Gianatti, Andrea
    Morelli, Luca
    Riva, Giulio
    Zagami, Maria Giovanna
    Fusco, Nicola
    Munari, Enrico
    L'Imperio, Vincenzo
    Pagni, Fabio
    Morbini, Patrizia
    Martini, Maurizio
    Eccher, Albino
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
  • [35] Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma
    Ralli, Megha
    Singh, Sunita
    Yadav, S. P. S.
    Sharma, Nisha
    Verma, Renuka
    Sen, Rajeev
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 232 - 237
  • [36] PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
    Evrard, D.
    Hourseau, M.
    Couvelard, A.
    Paradis, V.
    Gauthier, H.
    Raymond, E.
    Halimi, C.
    Barry, B.
    Faivre, S.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [37] Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
    Berghoff, Anna Sophie
    Ricken, Gerda
    Wilhelm, Dorothee
    Rajky, Orsolya
    Widhalm, Georg
    Dieckmann, Karin
    Birner, Peter
    Bartsch, Rupert
    Preusser, Matthias
    JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (01) : 19 - 29
  • [38] The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes
    Chen, Lu
    Cao, Mian-Fu
    Zhang, Xian
    Dang, Wei-Qi
    Xiao, Jing-Fang
    Liu, Qing
    Tan, Yu-Huan
    Tan, Yao-Yao
    Xu, Yuan-Yuan
    Xu, Sen-Lin
    Yao, Xiao-Hong
    Cui, You-Hong
    Zhang, Xia
    Bian, Xiu-Wu
    CANCER MEDICINE, 2019, 8 (17): : 7207 - 7218
  • [39] Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
    Cho, Young-Ah
    Yoon, Hye-Jung
    Lee, Jae-Il
    Hong, Sam-Pyo
    Hong, Seong-Doo
    ORAL ONCOLOGY, 2011, 47 (12) : 1148 - 1153
  • [40] Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma
    Ono, Takeharu
    Azuma, Koichi
    Kawahara, Akihiko
    Sasada, Tetsuro
    Hattori, Satoshi
    Sato, Fumihiko
    Shin, Buichiro
    Chitose, Shun-Ich
    Akiba, Jun
    Hirohito, Umeno
    ONCOTARGET, 2017, 8 (54) : 92699 - 92714